As a consequence, very recently, it was shown that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression could predict not only the metabolic status but also response to chemotherapy and specific metabolism-interfering therapy in DLBCL patients (36). Here, GAPDH is linked to diffuse large B-cell lymphoma.